The Butyrophilin Subfamily 3 Member A1 pipeline drugs market research report outlays comprehensive information on the Butyrophilin Subfamily 3 Member A1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Butyrophilin Subfamily 3 Member A1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, and Infectious Disease which include the indications Unspecified Cancer, Breast Cancer, Autoimmune Disorders, Unspecified Viral Infections, and Tuberculosis. It also reviews key players involved in Butyrophilin Subfamily 3 Member A1 targeted therapeutics development with respective active and dormant or discontinued products.
The Butyrophilin Subfamily 3 Member A1 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Preclinical stages are 1, and 4 respectively.
Butyrophilin Subfamily 3 Member A1 overview
Butyrophilin Subfamily 3 Member A1 (BTN3A1) is a transmembrane protein that belongs to the butyrophilin-like (BTNL) family. It is primarily expressed in various tissues, including immune cells, where it plays a role in modulating immune responses. BTN3A1 is particularly notable for its involvement in the activation of γδ T cells, a subset of T cells that contributes to both innate and adaptive immunity. One of the distinctive features of BTN3A1 is its association with the major histocompatibility complex class I-related molecule, MR1. This interaction is crucial for the presentation of microbial vitamin B metabolites to γδ T cells, thereby linking BTN3A1 to the detection of microbial infections. The activation of γδ T cells through the BTN3A1-MR1 axis is a key component of the immune surveillance against pathogens. Beyond its role in immunity, BTN3A1 has been implicated in various diseases, including cancer.
For a complete picture of Butyrophilin Subfamily 3 Member A1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
